Comparative Pharmacology
Head-to-head clinical analysis: FML FORTE versus IHEEZO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FML FORTE versus IHEEZO.
FML FORTE vs IHEEZO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorometholone is a synthetic corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. This results in suppression of inflammation, immune response, and fibroblast proliferation.
Iheezo (phentolamine ophthalmic solution) is an alpha-adrenergic antagonist that inhibits sympathetic tone to the iris dilator muscle, preventing mydriasis and facilitating pupil constriction during ocular surgery.
1 drop of 0.25% ophthalmic suspension in the conjunctival sac of the affected eye(s) every 4 hours. In severe conditions, 1 drop every 2 hours initially, taper as response is achieved.
1 drop in the affected eye(s) 3 times daily as needed for relief of ocular discomfort. For optimal use, administer at least 10 minutes apart from other ophthalmic medications.
None Documented
None Documented
Plasma terminal elimination half-life is approximately 3-4 hours (range 2-6 hours) for fluorometholone alcohol; clinical effects may persist longer due to tissue retention.
The terminal elimination half-life of proparacaine is approximately 1-2 minutes due to rapid hydrolysis by plasma esterases, resulting in a very short duration of systemic exposure.
Eliminated primarily via hepatic metabolism; renal excretion of inactive metabolites accounts for approximately 60-70%, with about 30-40% excreted in feces via bile.
IHEEZO (proparacaine) is predominantly metabolized by plasma esterases; less than 5% is excreted unchanged in urine. Biliary/fecal elimination is negligible.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid